- Conditions
- Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration
- Interventions
- bevacizumab, ranibizumab
- Biological
- Lead sponsor
- Outlook Therapeutics, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 228 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 50
- States / cities
- Tucson, Arizona • Arcadia, California • Beverly Hills, California + 46 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 110
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Macular Degeneration, Choroidal Neovascularization
- Interventions
- episcleral brachytherapy
- Radiation
- Lead sponsor
- Salutaris Medical Devices, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 2
- States / cities
- ‘Aiea, Hawaii • Oak Forest, Illinois
- Conditions
- Macular Degeneration
- Interventions
- Ranibizumab
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Neovascular (Wet) Age-Related Macular Degeneration
- Interventions
- EYC-0305
- Biological
- Lead sponsor
- Eyconis INC.
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 7
- States / cities
- Beverly Hills, California • Modesto, California • Wake Forest, North Carolina + 4 more
- Conditions
- Submacular Hemorrhage, Wet Macular Degeneration, Neovascular Age-related Macular Degeneration
- Interventions
- Anti-VEGF, Hemorrhage displacement + Anti-VEGF
- Drug · Other
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Age-Related Macular Degeneration
- Interventions
- NG101 AAV gene therapy
- Genetic
- Lead sponsor
- Elisigen, Inc.
- Industry
- Eligibility
- 50 Years to 89 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- CLS-AX, Anti-VEGF
- Drug
- Lead sponsor
- Clearside Biomedical, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Bakersfield, California • Mountain View, California + 8 more
- Conditions
- Neovascular Age-elated Macular Degeneration (Wet AMD), Exudative Macular Degeneration
- Interventions
- LFG316, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 7
- States / cities
- Tucson, Arizona • Torrance, California • Fort Myers, Florida + 4 more
- Conditions
- Age-Related Macular Degeneration
- Interventions
- E10030, ranibizumab, E10030 sham intravitreal injection
- Drug
- Lead sponsor
- Ophthotech Corporation
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 627 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 49
- States / cities
- Tucson, Arizona • Fresno, California • La Jolla, California + 43 more
- Conditions
- Age-related Macular Degeneration
- Interventions
- Brolucizumab 6 mg, Aflibercept 2 mg
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 734 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Huntington Beach, California • Loma Linda, California + 20 more
- Conditions
- Wet Age-related Macular Degeneration
- Interventions
- KSI-301, Aflibercept, Sham Procedure
- Drug · Other
- Lead sponsor
- Kodiak Sciences Inc
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 557 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 65
- States / cities
- Phoenix, Arizona • Springdale, Arkansas • Bakersfield, California + 60 more
- Conditions
- Age Related Macular Degeneration, Pigment Epithelial Detachment
- Interventions
- Aflibercept
- Drug
- Lead sponsor
- Tennessee Retina
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 3
- States / cities
- San Francisco, California • Lexington, Kentucky • Nashville, Tennessee
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- ADVM-022
- Genetic
- Lead sponsor
- Adverum Biotechnologies, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 34
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 30 more
- Conditions
- Age-Related Macular Degeneration
- Interventions
- E10030, bevacizumab or aflibercept, E10030 sham injection
- Drug
- Lead sponsor
- Ophthotech Corporation
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 645 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 100
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 88 more
- Conditions
- Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration
- Interventions
- SCD411, Aflibercept
- Drug
- Lead sponsor
- Sam Chun Dang Pharm. Co. Ltd.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 576 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 12
- States / cities
- Campbell, California • Clearwater, Florida • Coral Springs, Florida + 9 more
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- UBX1325 injection 50 μL, EYLEA® (aflibercept) Injection 2 mg (0.05mL)
- Drug
- Lead sponsor
- Unity Biotechnology, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 14
- States / cities
- Beverly Hills, California • Huntington Beach, California • Longmont, Colorado + 11 more
- Conditions
- Neovascular Age-related Macular Degeneration, Wet Macular Degeneration
- Interventions
- Dorzolamide-timolol, Artificial tears
- Drug · Other
- Lead sponsor
- Wills Eye
- Other
- Eligibility
- 45 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 5
- States / cities
- Palo Alto, California • Boston, Massachusetts • Royal Oak, Michigan + 2 more
- Conditions
- Neovascular Age Related Macular Degeneration
- Interventions
- Lucentis (Treat and extend), Lucentis every 4 weeks, Lucentis every 12 weeks
- Drug
- Lead sponsor
- Retinal Consultants of Arizona
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 4
- States / cities
- Gilbert, Arizona • Mesa, Arizona • Peoria, Arizona + 1 more
- Conditions
- Macular Degeneration, Age-Related Maculopathies, Age-Related Maculopathy, Maculopathies, Age-Related, Maculopathy, Age-Related, Retinal Degeneration, Retinal Neovascularization, Gene Therapy, Therapy, Gene, Eye Diseases
- Interventions
- AAV2-sFLT01
- Biological
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2018
- U.S. locations
- 4
- States / cities
- Baltimore, Maryland • Boston, Massachusetts • Worcester, Massachusetts + 1 more
- Conditions
- Age-related Macular Degeneration
- Interventions
- Fovista® (anti-PDGF BB) plus anti-VEGF
- Drug
- Lead sponsor
- Ophthotech Corporation
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Sacramento, California + 9 more
- Conditions
- Diabetic Macular Edema
- Interventions
- LKA651, Lucentis
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 7
- States / cities
- Beverly Hills, California • Rancho Cordova, California • Miami, Florida + 4 more
- Conditions
- Diabetic Macular Edema (DME), Neovascular Age-Related Macular Degeneration (nAMD)
- Interventions
- aflibercept 8 mg PFS
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 2
- States / cities
- Bellaire, Texas • The Woodlands, Texas
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- Intravitreal Aflibercept Injection 2mg
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 323 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 115
- States / cities
- Birmingham (2 Locations), Alabama • Phoenix (2 Locations), Arizona • Tucson (2 Locations), Arizona + 112 more
- Conditions
- Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
- Interventions
- Ixo-vec, Aflibercept
- Genetic · Drug
- Lead sponsor
- Adverum Biotechnologies, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 311 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 75
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 67 more